


HPV Testing and Pap Test Market to Reach \$6.7 Billion by 2031, Driven by Rising Cervical Cancer Screening Demand

PORTLAND, OR, UNITED STATES, August 19, 2025 /EINPresswire.com/ -- The global HPV testing and Pap test market was valued at \$3.7 billion in 2021 and is projected to reach \$6.7 billion by 2031, expanding at a CAGR of 6.1% from 2022 to 2031. The increasing prevalence of cervical cancer, growing awareness about women's health screening, and continuous advancements in diagnostic technologies are fueling the market's growth trajectory.



Market Overview

Human papillomavirus (HPV) is the most common sexually transmitted infection globally and a leading cause of cervical and vaginal cancers. Among the 200+ identified HPV strains, 14 highrisk types, particularly HPV 16 and 18, account for approximately 70% of cervical cancer cases worldwide. Early detection through HPV tests, Pap tests, or co-testing remains critical for timely intervention and prevention of cancer progression.

Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A14373

Healthcare guidelines recommend:

Women aged 21–29 years: Pap test every 3 years

Women aged 30–65 years: HPV test every 5 years, co-testing every 5 years, or Pap test every 3 years

This structured screening approach underpins the strong adoption of HPV and Pap tests across hospitals, clinics, and diagnostic centers.

Market Dynamics

Growth Drivers

Rising Cervical Cancer Burden: According to the American Society of Clinical Oncology, Africa alone represents 20% of global cervical cancer cases, with 120,000 new cases annually.

Innovation in Screening Kits: Companies are developing specific HPV type testing kits and self-sampling solutions to enhance detection and accessibility.

Awareness & Preventive Healthcare: Increasing public and government initiatives for routine cervical screening are boosting demand globally.

For instance, in 2021, Roche received FDA approval for its cobas HPV test, enabling precise detection of high-risk HPV DNA in cervical samples. In 2022, Roche also launched an HPV self-sampling solution in CE-mark-accepting countries, further expanding access to screening.

Restraints

Changing Screening Guidelines: Shifting clinical recommendations may create uncertainty for testing frequency.

HPV Vaccination Programs: The growing global adoption of HPV vaccines could reduce long-term demand for some screening services.

Opportunities

Technological Advancements: Al-powered diagnostics and molecular HPV assays are expanding clinical accuracy.

Emerging Economies: Countries like China and India are rolling out free, population-based cervical cancer screening programs, creating significant growth opportunities.

Segmental Insights

By Test Type:

Pap test dominated the market in 2021 due to its wide adoption.

Co-test is expected to grow fastest (CAGR 8.6%) owing to superior accuracy in cervical cancer detection.

By Application:

Cervical cancer screening accounted for the largest share and is projected to grow at a CAGR of 6.3%.

By Location of Testing: Diagnostic centers held the leading share in 2021, offering precise and large-scale screening services. Self-sampling/home-based kits are expected to grow at 6.7% CAGR, driven by convenience and privacy. By Region: North America led the market in 2021, backed by strong healthcare infrastructure and awareness programs. Asia-Pacific is expected to record the highest growth rate, supported by government-led free screening programs and the presence of leading diagnostic companies. Competitive Landscape Key players shaping the market include: Abbott Laboratories **Arbor Vita Corporation** Becton, Dickinson and Company (BD) F. Hoffmann-La Roche AG Hologic Inc. Qiagen NV Seegene Inc. Thermo Fisher Scientific Inc. **Femasys** Mylab Discovery Solutions Pvt. Ltd. Strategies such as product approvals and new test launches remain central. For instance, BD received FDA approval in 2020 for its expanded BD Onclarity HPV assay, strengthening its

diagnostic portfolio.

Outlook

Despite temporary setbacks during the COVID-19 pandemic, the HPV testing and Pap test market is rebounding, with stable growth expected over the next decade. Rising awareness, policy support, and the development of more precise and patient-friendly screening technologies will continue to shape market expansion.

Enquire Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/A14373

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube
X

This press release can be viewed online at: https://www.einpresswire.com/article/841204719

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.